Rensselaer researchers receive $3.5 million grant for development of COVID antiviral drug
TROY, N.Y. — Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from ...
Tag: antiviral
Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by Biomedical Sciences researchers
ATLANTA—An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of ...
Journal of Pharmaceutical Analysis publishes method for the fast detection of a key antiviral
Interferons are proteins that constitute an important part of our natural defense systems. These proteins also exhibit a remarkable antiviral ...
UNC-Chapel Hill receives $65M from NIH for antiviral drug development center
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of ...
NIAID announces antiviral drug development awards
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 ...
Potent intracellular antiviral activity of human IgG3 hinge on the hinge
Humans have developed four different IgG antibody subclasses that orchestrate protection against invading pathogens. A molecular and cellular understanding of ...
WHO strongly recommends antiviral drug for patients with non-severe COVID-19
Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe covid-19 who ...
Scientists develop indoor-active photocatalyst for antiviral coating against various variant types of novel coronavirus SARS-CoV-2
Photocatalyst made using a combination of titanium dioxide (TiO2) and copper oxide (CuxO) nanoclusters inactivates various variant types of novel ...
Data from investigational COVID-19 antiviral drug molnupiravir suggest better outcomes for most COVID-related symptoms than placebo
**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID ...
New virology data shows the investigational COVID antiviral drug molnupiravir eliminates actively infectious SARS-CoV-2 virus by day 3 of starting therapy
**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID ...
New analysis of investigational COVID antiviral drug molnupiravir shows it appears to clear virus equally well in immunocompromised patients and those who are immunocompetent
**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID ...
ACTG and Shionogi announce progress on global phase 3 trial of novel COVID-19 oral antiviral agent S 217622
FDA has cleared the IND for S-217622, a once-daily investigational oral antiviral therapy, enabling the global phase 3 trial to ...
Novel antiviral drug combinations demonstrate COVID-19 therapeutic potential
New York, NY—March 7, 2022—Researchers from Columbia Engineering, Fiocruz’s Center for Technological Development in Health and the Oswaldo Cruz Institute ...
WHO recommends antiviral drug for patients with non-severe COVID-19 at highest risk of hospital admission
The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalisation, says ...
Hepatitis C patients cured with antiviral medicines are less likely to be hospitalized, need ER care for liver, other health-related issues
DETROIT (February 18, 2022) – Researchers at Henry Ford Health System, as part of a national hepatitis C collaborative, report ...
*Free* Lethal mutagenesis: a viable antiviral strategy with unknown risks
In a Perspective, Ronald Swanstrom and Raymond Schinazi argue that antiviral drugs that lead RNA viruses to produce genetic mutations ...
Georgia State University Center for Translational Antiviral Research reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2
Credit: Georgia State University ATLANTA—The COVID-19 pandemic and resurgence of infections by other respiratory RNA viruses such as respiratory ...
Antiviral treatment for hepatitis C virus reduces risk of post-treatment liver cancer progression, study shows
OSAKA, Japan — In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease ...
UBC-led researchers uncover how the novel coronavirus escapes a cell’s antiviral defences
A UBC-led research team has uncovered how the virus responsible for causing COVID-19 escapes destruction in infected cells, allowing SARS-CoV-2 ...
KU Leuven develops very potent antiviral against dengue
Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes ...
-
Male dogs four times more likely to develop contagious cancer on nose or mouth than females
-
Atezolizumab translates into survival benefit for bladder cancer patients with ctDNA positivity
-
Asthmatics may soon breathe easier thanks to new breakthrough
-
COVID-19 fattens up our body’s cells to fuel its viral takeover
-
Only through international cooperation can AI improve patient lives
-
New imaging technology less accurate than MRI at detecting prostate cancer, trial shows